Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmX TechnologiesASX:PHX +10.00%35 EV-to-EBITDA is 105.01 as of Aug. 02, 2026, which is 845% above its 10-year median of 11.11. GuruFocus rates ASX:PHX with a GF Score™ of 35/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 509 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 95.28% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmX Technologies's enterprise value is A$70.78 Mil.
PharmX Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.67 Mil. Therefore, PharmX Technologies's EV-to-EBITDA for today is 105.01.
The historical rank and industry rank for PharmX Technologies's EV-to-EBITDA or its related term are showing as below:
ASX:PHX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -151.43 Med: 11.11 Max: 105.01
Current: 105.01
During the past 13 years, the highest EV-to-EBITDA of PharmX Technologies was 105.01. The lowest was -151.43. And the median was 11.11.
ASX:PHX's EV-to-EBITDA is ranked worse than 95.28% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.07
vs ASX:PHX: 105.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmX Technologies's PE Ratio (TTM) for today is calculated as:
PharmX Technologies's share price for today is A$0.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PharmX Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PHX vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, PharmX Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's EV-to-EBITDA falls into.
PharmX Technologies's current Enterprise Value is A$70.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmX Technologies (ASX:PHX) has a EV-to-EBITDA of 105.01 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmX Technologies. This is 845% above median its historical median of 11.11. According to the industry distribution chart, PharmX Technologies ranks #485 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 95.3%.
Is PharmX Technologies' EV-to-EBITDA too high?
PharmX Technologies' current EV-to-EBITDA of 105.01 is 845% above median its 10-year median of 11.11. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.07. PharmX Technologies' value of 105.01 is 848.6% above this industry median. Based on the distribution chart, PharmX Technologies ranks #485 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmX Technologies has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #485 out of 509 companies for EV-to-EBITDA. This places PharmX Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 11.07. PharmX Technologies' value of 105.01 is 848.6% above this benchmark. While the company's 10-year median is 11.11 vs. the industry median of 11.07, PharmX Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.07, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmX Technologies's current EV-to-EBITDA of 105.01 is 848.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmX Technologies. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current EV-to-EBITDA is 105.01, which is 845% above median its own 10-year median of 11.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.11 — trading 57.1% above its estimated fair value. The current EV-to-EBITDA is 105.01, which is 845% above median its 10-year median of 11.11 and 848.6% above the Healthcare Providers & Services industry median of 11.07. PharmX Technologies' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current EV-to-EBITDA is 105.01 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.11 is trading 57.1% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
EV-to-EBITDA: 105.01 (845% above median its 10-year median of 11.11)
GF Value™: A$0.07 vs. price of A$0.11 (57.1% above fair value)
Industry Position: 848.6% above the Healthcare Providers & Services median (#485 of 509)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
35GF Score
Get the complete analysis for ASX:PHX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
